《Table 1Outcomes adopted in the protocols of clinical trials on COVID-19.》

《Table 1Outcomes adopted in the protocols of clinical trials on COVID-19.》   提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《新冠病毒肺炎临床试验核心指标集》


  1. 获取 高清版本忘记账户？点击这里登录
  1. 下载图表忘记账户？点击这里登录

The consensus meeting was held on 24 February 2020，and involved 20 participants.These included representatives from various stakeholder groups who were experts in respiratory，critical，TCM，and evidence-based medicine；clinical pharmacology；and statistics，in addition to medical journal editors and decisionmakers.There was no conflict of interest among the different stakeholders.Before discussion on each outcome，the results of the two rounds of Delphi survey were shown to the participants of the meeting.Based on the Delphi survey results and discussion，the participants voted anonymously for each outcome，following the criteria of clinical value，clinical feasibility，and stability ofindicators in different classifications of COVID-19.Each outcome that met the consensus standards was included in the final COS.At the end，the COS-COVID consisted of one outcome for mild（time to 2019 novel coronavirus （2019-n Co V）reverse transcription-polymerase chain reaction（RT-PCR）negativity），four outcomes for ordinary （length of hospital stay，composite events，score of clinical symptoms，and time to 2019-n Co V RT-PCR negativity），five outcomes for severe （composite events，length of hospital stay，arterial oxygen partial pressure (Pa O2）/fraction of inspired oxygen（Fi O2），duration of mechanical ventilation，and time to 2019-n Co V RT-PCR negativity)，one outcome for critical （all-cause mortality），and one outcome for rehabilitation period （pulmonary function），as shown in Table 5.

图表编号XD00195687400    严禁用于非法目的
绘制时间2020.10.01
作者金鑫瑶、庞博、张俊华、刘清泉、杨忠奇、封继宏、刘学政、张磊、王保和、黄宇虹、Alice Josephine Fauci、马玉玲、Myeong Soo Lee、元唯安、谢雁鸣、唐健元、高蕊、杜亮、张硕、祁寒梅、孙宇、郑文科、杨丰文、蔡慧姿、王可仪、欧益、黄明、朱彦、喻佳洁、田金徽、赵敏、胡镜清、姚晨、李幼平、张伯礼
绘制单位Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine、Chinese Clinical Trials Core Outcome Set Research Center、Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine、Chinese Clinical Trials Core Out
更多格式高清、无水印（增值服务）

相关图表

  1. 《Table 3 Sensitivity coefficients of parameters in the CO2RR model adopting bi-function mechanism》2020.05.10
  2. 《Table 2 Sensitivity coefficients of parameters in the CO2RR model adopting single site mechanism》2020.05.10
  3. 《Table 1 Clinical trials classified on molecular targets》2019.10.15
  4. 《Table 1 Clinical trials classified on molecular targets》2019.10.15
  5. 《Table 1 Clinical trials classified on molecular targets》2019.10.15
  6. 《Table 1 Clinic features of the patients in the pedigree》2019.05.18
  7. 《表2 Clinicaltrials.gov不同药物的临床研究状态Tab 2 Clinical trials Status of drugs on the Clinicaltrials.gov wed》2019.01.28
  8. 《Table 1.Clinical data of the patients in 3 three groups》2019.02.20
  9. 《Table 1 AAV-mediated gene therapy in clinical trials for neurodegenerative diseases in the central nervous system》2019.06.01
  10. 《Table 2 Preoperative clinical data of the eyes included in the study in both subgroups》2019.04.18
  11. 《Table 2 Land cover classification system adopted in remote sensing based mapping on wetlands of international importance》2017.06.29
  12. 《Table 1 Clinical data of patients in the 2 groups》2018.05.01
  13. 《Table 1 Clinical data of patients in the 2 groups》2018.05.01
  14. 《Table 1 Clinical data of patients in the 2 groups》2018.05.01
  15. 《Table 1 Basic properties of topsoil in the trial sites》2018.08.01
  16. 《Table 1 Demographic and clinical characteristics of the study groups based on the diagnosis in 168 eyes of 168 subjects》2018.05.18
  17. 《Table 4Recent clinical trials of SMP and COR.》2018.10.15
  18. 《Table 3Recent clinical trials of NMP.》2018.10.15
  19. 《Table 2Recent clinical trials of HMP.》2018.10.15
  20. 《Table 1Characteristics of the 14 trials included in the meta-analysis.》2018.02.01

随机翻阅

《表1 患者一般临床资料比较》 《表3 可交换债与股票质押融资成本比较》 《表2 两组护理质量评分对比（±s，分）》 《表3 2009年腾冲县城区（住宅用地）土地基准地价》 《表1 两组患者治疗前、后外周血Th1/Th2细胞因子水平比较（n=27,,pg/mL)》 《表1 介质参数各层分布表》 《表3 婴幼儿喂养方式的logistic回归分析》 《表1 瓷板铺贴合格率要因确认表》 《表1 患者化疗方案及其他化学药品用药情况》 《表3 不同水体沉积物中OCPs含量Tab.3 Comparison of OCP concentrations in surface sediments from different water bodies》